=========================================================

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON D.C. 20549

 

FORM 8-A

 

FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES

PURSUANT TO SECTION 12(b) OR 12(g) OF THE

SECURITIES EXCHANGE ACT OF 1934

 

Moleculin Biotech, Inc.

___________________________________________

(Exact Name of Registrant as Specified in Its Charter)

  

  Delaware   47-4671997  
         
   (State of Incorporation or Organization)   (I.R.S. Employer Identification No.)  
         
  2575 West Bellfort, Suite 333   77054  
  Houston, Texas      
         
  (Address of Principal Executive Offices)   (Zip Code)  
         
  Title of each class   Name of each exchange on which  
  to be so registered   each class is to be registered  
         
  Common Stock, par value $0.001 per share   The NASDAQ Stock Market LLC  

 

  

If this form relates to the registration of a securities pursuant to Section 12(b) of the Exchange Act and is effective upon filing pursuant to General Instruction A.(c), please check the following box. x

 

If this form relates to the registration of a class of securities pursuant to Section 12(g) of the Exchange Act and is effective pursuant to General Instruction A.(d), please check the following box. ¨

 

 

Securities Act registration statement file number to which this form relates: 333-209323

 

 

Securities to be registered pursuant to Section 12(g) of the Act: None

 

 

 

 

Item 1. Description of Registrant’s Securities to be Registered .

 

Moleculin Biotech, Inc. (the “Registrant”) hereby incorporates by reference the description of its common stock, par value $0.001 per share, to be registered hereunder contained under the heading “Description of Capital Stock” in the Registrant’s Registration Statement on Form S-1 (File No. 333-209323) (the “Registration Statement”), and in the prospectus included in the Registration Statement to be filed separately by the Registrant with the Commission pursuant to Rule 424(b) under the Securities Act of 1933, as amended, which prospectus shall be deemed to be incorporated by reference herein.

 

Item 2. Exhibits.

 

In accordance with the “Instructions as to Exhibits” with respect to Form 8-A, no exhibits are required to be filed as part of this registration statement because no other securities of the Registrant are registered on the Nasdaq Stock Market and the securities registered hereby are not being registered pursuant to Section 12(g) of the Securities Exchange Act of 1934, as amended.

 

SIGNATURE

 

 

Pursuant to the requirements of Section 12 of the Securities Exchange Act of 1934, the registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereto duly authorized.

 

Dated: April 27, 2016

 

  Moleculin Biotech, Inc.  
       
       
  By: /s/ Louis Ploth  
    Louis Ploth, Chief Financial Officer